🇺🇸 FDA
Patent

US 10813918

Use of Gaboxadol in the treatment of diabetes and related conditions

granted A61KA61K31/155A61K31/437

Quick answer

US patent 10813918 (Use of Gaboxadol in the treatment of diabetes and related conditions) held by OVID THERAPEUTICS INC. expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/155, A61K31/437, A61K31/4985, A61K45/06